Interest of FDG-PET in the Management of Mantle Cell Lymphoma - Archive ouverte HAL Accéder directement au contenu
Article Dans Une Revue Frontiers in Medicine Année : 2019

Interest of FDG-PET in the Management of Mantle Cell Lymphoma

Résumé

FDG-PET changed response assessment and therapy strategy in diffuse large B-cell lymphoma and Hodgkin disease lymphoma. The value of FDG-PET evaluation in MCL has not been extensively studied and a recent expert consensus highlighted the need for more studies addressing this question. Data of the literature show the value of FDG-PET at baseline in patients with MCL, underlining the good sensitivity of this examination for the initial staging of this pathology, but also the potential impact of semi-quantitative analysis in this indication. The determination of SUVmax at diagnosis might indeed provide important prognostic information. Some studies also suggest the potential value of early and end-of-treatment metabolic assessment in MCL, but these results need to be validated in standardized prospective studies. These results also underlie the need to integrate FDG-PET results into MCL treatment strategy to improve disease management in identifying patients who might benefit from more intensive therapy.

Domaines

Cancer
Fichier principal
Vignette du fichier
BaillyEq13-2019.pdf (121.27 Ko) Télécharger le fichier
Origine : Fichiers éditeurs autorisés sur une archive ouverte
Loading...

Dates et versions

inserm-02100231 , version 1 (15-04-2019)

Identifiants

Citer

Clément Bailly, Thomas Carlier, Cyrille Touzeau, Nicolas Arlicot, Françoise Kraeber-Bodéré, et al.. Interest of FDG-PET in the Management of Mantle Cell Lymphoma. Frontiers in Medicine, 2019, 6, Epub ahead of print. ⟨10.3389/fmed.2019.00070⟩. ⟨inserm-02100231⟩
104 Consultations
74 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More